title: Phase II study of carbetimer in non-small cell lung cancer.
authors.affiliation: Brooke Army Medical Center, Fort Sam Houston, TX.
authors.forename: M
authors.initials: M
authors.lastname: Keaton
authors.forename: T
authors.initials: T
authors.lastname: Brown
authors.forename: J
authors.initials: J
authors.lastname: Craig
authors.forename: G
authors.initials: G
authors.lastname: Fries
authors.forename: G
authors.initials: G
authors.lastname: Harmon
authors.forename: A
authors.initials: A
authors.lastname: Zaloznik
authors.forename: G
authors.initials: G
authors.lastname: Orczyk
authors.forename: D
authors.initials: D
authors.lastname: Von Hoff
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011108:Polymers / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D011108:Polymers; C022084:carboxyimamidate